Pre-Conference Workshop Day
Tuesday, February 27
8:00 am Workshop Check In, Coffee & Light Breakfast
Workshop A
9:00 am Next-Generation In Vivo Immune Engineering Platforms: Considerations & Learnings to Optimise Transfer
Synopsis
Attend this workshop to:
- Understand the differences, advantages and limitations of both ex vivo and in vivo approaches
- Evaluate engineering methods and delivery platforms to ensure specific CAR expression in target tissue
- Evaluate in vivo modalities from lipid nanoparticles to viral vectors to outline options for cost, payload and scalability
- Discuss the possibility for in vivo engineering in innate immune cells as well as applicability to non-oncology indications
Workshop B
9:00 am Harnessing Combination & Co-Stimulation Approaches to Boost Efficacy, Persistence & Improve Clinical Outcomes
Synopsis
Attend this workshop to:
- Evaluate possible combination agents for cell therapies to improve expansion rates, prime the tumour microenvironment or promote survival
- Understand how different therapies can work synergistically to boost clinical efficacy to optimise dosing and administration
- Implement combination therapies into clinical design to ensure patient safety and regulatory compliance
Workshop C
9:00 am Implementing & Managing a Point of Care Manufacturing Model to Reinvent Vein-to-Vein Times & Boost Accessibility
Synopsis
Attend this workshop to:
- Reduce supply chain complexity and cost of goods by manufacturing cell therapies at clinical sites
- Overcome analytical challenges and time constraints when working with fresh apheresis
- Understand onboarding clinical sites and training clinicians to produce cell therapy products
- Consolidate regulatory guidance for Point of Care manufacture to ensure compliance
12:00 pm Lunch Break & Networking
Workshop D
1:00 pm Incorporating Modular Control into Cell Therapies through Receptors to Enhance Therapy Persistence & Safety
Synopsis
Attend this workshop to:
- Assess options to achieve modular control such as logic gating and switch receptors to boost specific efficacy at tumour site
- Implement a switch receptor to allow precise control of cells to minimise toxicity
- Educate clinicians on when and how to use switch receptors to modulate or terminate expression levels in patients
Workshop E
1:00 pm Optimising Clinical Trial Design & Endpoint Determination to Accelerate Trial Progression
Synopsis
Attend this workshop to:
- Innovate clinical trial design to cater for more complex cell therapy products and combinations
- Evaluate best-practice for dosing, biomarker development, patient selection and regulatory compliance
- Outline how endpoints alter between early and late stage trials
- Compare novel exploratory endpoints (e.g. ctDNA) to define potential for cell therapies
Workshop F
1:00 pm Accelerating Analytical Testing to Facilitate Rapid Product Release & Decrease End-to-End Production Time
Synopsis
Attend this workshop to:
- Analyse current analytical processes to identify areas with potential to streamline and improve turnaround time
- Incorporate analytical testing into automated processe to minimise error and support predictable outcomes
- Shorten quality release timelines while maintaining reliability to accelerate release of high quality products
4:00 pm Afternoon Break & Refreshments
4:30 pm C-Level Think Tank (Invite Only)
Synopsis
An exclusive opportunity for top C-level executives from biotech & senior executives from pharma to collaborate and discuss the most pressing challenges the CAR-TCR community are facing in Europe
4:30 pm Driving Diversity in CAR-TCR (Free to Attend)
Synopsis
- Diversity in the Workplace: Ensuring diverse representation throughout the cell therapy space
- Diversity in Clinical Trials: Extending patient populations to include subgroups and minorities to ensure ethnic inclusion and reduce disparities
6:00 pm Refreshment Break
6:15 pm Investor & Biopharma Partnerships Evening
Synopsis
After a challenging year for cell therapy investment, join this session spotlighting big pharma, VC and investor perspectives on the current market and opportunities to stem a conversation on how investment into this promising space can be reinvigorated.